<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate the effects of administration of hyperbaric oxygenation(HBO) when initiated at different time after <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022118" disease_type="Disease or Syndrome" abbrv="">transient ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> in the ischemic penumbra was further investigated to search for the possible mechanism </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The male SD rats were randomly assigned to the following groups: control, HBO therapy initiated 3 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, HBO therapy initiated 6 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, HBO therapy initiated 12 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> animals were subjected to 90 min intraluminal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) with the regional cerebral blood flow monitored in vivo by laser Doppler flowmetry </plain></SENT>
<SENT sid="4" pm="."><plain>HBO treatment was performed in a pressure chamber with 100% O2, 3 arm for 1 h </plain></SENT>
<SENT sid="5" pm="."><plain>Neurological deficits and <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes were assessed at 24 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The immunohistochemical changes of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the penumbra were evaluated by detecting the expression of cleaved Caspase-3, cleaved Caspase-9, Bcl-2, Bax and TUNEL staining </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: HBO therapy initiated at 3 and 6 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> significantly improved the neurological function and reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="8" pm="."><plain>Meanwhile, it increased the expression of Bcl-2 protein and decreased the expression of activated Caspase-3, activated Caspase-9 and TUNEL-positive cells </plain></SENT>
<SENT sid="9" pm="."><plain>However, HBO therapy administrated 12 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> aggravated the neurological deficits and enlarged <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, while it showed no significant reduction of apoptotic change compared with control </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: There is a therapeutic window for the use of HBO in <z:hpo ids='HP_0011009'>acute</z:hpo> transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="11" pm="."><plain>HBO-treatment is highly effective in reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when initiated up to 6h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Inhibition of apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> in the penumbra appears to be the underlying protective effect of early therapy </plain></SENT>
</text></document>